In addition to the substantial data relevant to the MOA of FL118 through DDX5 (Figures 1, 2, 3, 4) presented in this report, we have also provided extensive in vitro and in vivo data to determine whether DDX5 could be used as an FL118 target and biomarker for predicting PDAC and CRC tumour sensitivity to FL118 treatment (Figures 5, 6, 7, 8, 9). Here, DDX5 is linked to colorectal carcinoma.